Poolbeg Pharma ‘well-positioned to deliver’ for shareholders as it announces £10m cash balance

Poolbeg Pharma announces ‘milestone’ cancer therapy clinical trial agreement

Former Glen Dimplex boss acquires 5.74% stake in Poolbeg Pharma

Poolbeg Pharma could reach €1bn valuation, says chief executive

Poolbeg Pharma uses AI to identify possible drug targets for treatment of flu

Oral vaccines for Covid-19 expected by 2030

Biotech veteran Friel to list Poolbeg Pharma on Nasdaq using new deals

Biotech veteran Friel to list Poolbeg Pharma on Nasdaq using new deals

Shares in Poolbeg Pharma begin trading on the US venture market

Poolbeg Pharma lands deal with AI firm to pinpoint effective virus drugs

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.